Bayer and Mylan put generic dispute to rest

Bayer Healthcare and Mylan have settled their differences over a generic version of Bayer’s liver cancer drug Nexavar (sorafenib tosylate).

On Thursday, October 26, the parties filed a stipulation to dismiss the dispute at the US District Court for the District of Delaware.

The claim was dismissed with prejudice and the parties will bear their own costs and attorneys’ fees.

Bayer had sued Mylan in January 2015, in an attempt to stop the company from developing a generic version of Nexavar.

The patents Mylan was accused of infringing were US numbers 8,618,141, titled “Aryl ureas with angiogenesis inhibiting activity”, and 8,877,933, called “Thermodynamically stable form of a tosylate salt”.

Mylan had notified Bayer in December 2014 that it had filed an Abbreviated New Drug Application with the US Food and Drug Administration.

In 2014, Bayer lost an attempt to block a generic of Nexavar in India, after the Supreme Court of India rejected Bayer’s appeal from the Bombay High Court.

The Bombay court had backed a 2012 ruling by the Controller General of Patents to grant a compulsory licence to Natco Pharma, an Indian generics company, to market its own version of the drug.

Did you enjoy reading this story?  Sign up to our free newsletters and get stories like this sent straight to your inbox.